DMT

Studies and reports from the U.S. Department of Veterans Affairs (VA) and other research publications suggest that an estimated 20-30% of U.S. veterans may experience some form of mental health disorder, with depression and anxiety ranking high amongst conditions.  According the New England...

Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E...

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug...